|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In a sample of both 83 healthy individuals and 105 young patients with coronary artery disease from Sweden, the frequency of the 4G allele is roughly 0.5, and those individuals homozygous for the 4G allele have higher levels of PAI-1 than those with other genotypes (29% higher).
|
1456879 |
1992 |
|
Coronary Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Familial high PAI levels with concurrent hypofibrinolysis co-segregated with familial combined hyperlipidemia, both being independent risk factors for premature coronary heart disease.
|
8191398 |
1994 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes.
|
8560407 |
1995 |
|
Coronary Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increased plasminogen-activator inhibitor 1 (PAI-1) activity is a common finding in patients with coronary heart disease.
|
7892190 |
1995 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that PAI-1 promoter polymorphism influences the development of myocardial infarction through its effect on thrombus formation in patients with preexisting coronary atheroma.
|
9012634 |
1997 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Results from these studies further suggest that individuals with this responsive 2/2 PAI-1 genotype may reflect the additional inherent potential for later HTG-VLDL- or Lp(a)-induced fibrinolytic dysfunction, resulting in the early initiation of thrombosis, atherogenesis, and coronary artery disease.
|
9409314 |
1997 |
|
Coronary Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Circulating (PAI-1) levels are elevated in patients with coronary heart disease and may play an important role in the development of atherothrombosis.
|
9198234 |
1997 |
|
Coronary Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increased plasma plasminogen activator inhibitor-1 (PAI-1) concentration has been identified as a risk factor for coronary heart disease.
|
9445260 |
1998 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
An insertion or deletion (I/D) polymorphism in the angiotensin converting enzyme (ACE) gene and a 4/5-guanine tract polymorphism (4G/5G) in the promoter region of the plasminogen activator inhibitor-1 (PAI-1) gene are associated with the plasma activities of these substances and with coronary heart disease.
|
9844142 |
1998 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease.
|
9484978 |
1998 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recent evidence is accumulating that some clotting factors (fibrinogen, factor VII, von Willebrand factor) and fibrinolytic factors (t-PA and PAI-1) are associated with an increased risk of coronary artery disease.
|
9519344 |
1998 |
|
Coronary Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 (PAI-1) has been shown to be an independent risk factor for coronary artery disease.
|
9812921 |
1998 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The 4G/5G polymorphism of the PAI-I gene influenced not only plasma PAI-I antigen levels but also the time course of the progression to ACS in patients with coronary atherosclerosis.
|
9544737 |
1998 |
|
Coronary Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Reduced fibrinolytic capacity due to increased plasminogen activator inhibitor-1 (PAI-1) activity in plasma is a common finding in patients with coronary heart disease or venous thromboembolism, although its clinical significance is debated.
|
9569196 |
1998 |
|
Coronary Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We evaluated the relationship between the 4G/5G polymorphism and plasma PAI-1 antigen levels in 104 Japanese males not taking lipid-lowering drugs and without non-insulin-dependent (type 2) diabetes mellitus or coronary artery disease.
|
10641442 |
1999 |
|
Coronary Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease.
|
10235431 |
1999 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present data indicate that the 4G/4G genotype of the PAI-I gene polymorphism is an independent risk factor for coronary artery disease and that the additional presence of major cardiovascular risk factors accelerates the risk for this disease.
|
10494775 |
1999 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction.
|
10577569 |
1999 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Single effects of apolipoprotein B, (a), and E polymorphisms and interaction between plasminogen activator inhibitor-1 and apolipoprotein(a) genotypes and the risk of coronary artery disease in Czech male caucasians.
|
10720441 |
2000 |
|
Coronary Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The ApoE polymorphism may accelerate the development of coronary heart disease often seen in Caucasian patients with type 1 diabetes and diabetic nephropathy, a condition characterized by elevated plasma PAI-1 in men.
|
10809802 |
2000 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and coagulation factor VII Arg353-->Gln polymorphism in Korean patients with coronary artery disease.
|
10803689 |
2000 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We studied the frequency distribution of the PAI-I gene to test the hypothesis that the 4G/4G genotype favors myocardial ischemia and, even in the absence of acute infarction, promotes SCD in patients with CAD.
|
11457467 |
2001 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association of angiotensin converting enzyme and plasminogen activator inhibitor-1 promoter gene polymorphisms with features of the insulin resistance syndrome in patients with premature coronary heart disease.
|
11427204 |
2001 |
|
Coronary Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although the potential role of plasminogen activator inhibitor-1 (PAI-1) in the development of coronary artery disease is strongly supported by its biological characteristics, results of clinical studies remain controversial.
|
14629464 |
2003 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The interleukin-6 (IL-6) gene promoter G-174C polymorphism has been associated with insulin resistance, hypertension, and coronary artery disease; however, its relationship with plasma PAI-1 level has not yet been studied.
|
15831362 |
2005 |